Castle biosciences presents new data demonstrating the clinical utility and value of decisiondx®-scc in moderately and poorly differentiated cutaneous squamous cell carcinoma tumors

Friendswood, texas--( business wire )--castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced new data showing how the company's decisiondx®-scc test can provide objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma (cscc) tumors with uncertainty in differentiation status. the data were shared in an oral presentation given at the american society of dermatopathology (asdp) 59th annual meeting by sarah estrada, m.d., dermatopathologist with affiliated dermatology in scottsdale, arizona.
CSTL Ratings Summary
CSTL Quant Ranking